Trial Profile
Phase II Trial Assessing the Efficacy of a Reduced Dose Strategy of Darunavir to 400 mg/d in HIV-1 Infected Patients Virologically Suppressed Under a Once Daily Regimen Including Darunavir 800 mg/d and Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), to Maintain the Viral Load Lower Than 50 Copies / mL at 48 Weeks of Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DARULIGHT
- 13 Jun 2018 Results of ANRS 165 DARULIGHT sub-study (n=15) published in the Journal of Antimicrobial Chemotherapy
- 01 Jun 2018 Results published in the Journal of Antimicrobial Chemotherapy.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science.